Table 1.
Immunotherapy in PolE mutant cancers.
| PolE Mutation | Cancer Type | Tumor Mutation Burden | Immunotherapy | Overall Best Response | Reference |
|---|---|---|---|---|---|
| somatic V411L | metastatic EC | 4500 to 6500 nonsynonymous mutations | pembrolizumab | PR | [49] |
| germline V424L | glioblastoma | 17,276 to 20,045 mutations | pembrolizumab | PR | [38] |
| somatic V411L | metastatic CRC | 122 mutations per Mb | pembrolizumab | PR | [50] |
| somatic V411L | metastatic CRC | NA | pembrolizumab | CR | [51] |
| somatic P286R | metastatic CRC | NA | pembrolizumab | PD | [51] |
| somatic P286R | metastatic CRC | NA | pembrolizumab | SD | [51] |
EC, Endometrial Cancer; CRC, Colorectal Cancer; PR, Partial Response; CR, Complete Response; PD, Progressive Disease; SD, Stable Disease.